---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-001166"
form_type: "8-K"
ticker: null
cik: "0001792581"
company_name: "Kiromic Biopharma, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:31:39.696359+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiromic BioPharma issues $2M 25% senior secured convertible note due Feb 2025

## Summary
- Principal $2,000,000, interest 25% p.a. (27% upon default), matures Feb 12, 2025.
- Convertible at $2.50/share into common stock (KRBP), subject to 9.99% beneficial ownership cap.
- Note is senior secured; collateral includes all fixtures, equipment, and intellectual property.
- Issued to an accredited investor in reliance on Section 4(a)(2) exemption.

## SEC filing metadata
- accession: 0001558370-24-001166
- form_type: 8-K
- cik: 0001792581
- company_name: Kiromic Biopharma, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792581/000155837024001166/0001558370-24-001166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792581/000155837024001166/krbp-20240212x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-001166
- JSON: https://secwatch.observer/filing/0001558370-24-001166.json
- Plain text: https://secwatch.observer/filing/0001558370-24-001166.txt

## Key facts
- Debt Financings
  Kiromic Biopharma, Inc. incurred convertible notes of $2,000,000 with an accredited investor at 25% per annum maturing February 12, 2025.
  - Instrument: convertible notes
  - Principal: $2,000,000
  - Counterparty: an accredited investor
  - Rate: 25% per annum
  - Maturity: February 12, 2025
  - Event: incurrence
  source text: On February 12, 2024, Kiromic BioPharma, Inc. (the "Company") issued a 25% Senior Secured Convertible Promissory Note (the "Note") to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the "Stated Rate") and matures on February 12, 2025 (the "Maturity Date"), on which the principal balance and accrued but unpaid interest under the Note shall be due and payable.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1792581/000155837024001166/0001558370-24-001166-index.htm
- Material Agreements
  Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note with an accredited investor valued at $2,000,000 (effective 2024-02-12).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: an accredited investor
  - Value: $2,000,000
  - Effective: 2024-02-12
  source text: On February 12, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1792581/000155837024001166/0001558370-24-001166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.